Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2011-04-26
2011-04-26
Anderson, Rebecca L (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S397000, C548S335100
Reexamination Certificate
active
07932281
ABSTRACT:
Amine compounds represented by Formula (1) are efficacious against diseases such as a viral infectious disease with HIV, rheumatism, and cancer metastasis:
REFERENCES:
patent: 3634316 (1972-01-01), Ito et al.
patent: 5086069 (1992-02-01), Klein et al.
patent: 5633231 (1997-05-01), Habich et al.
patent: 5886044 (1999-03-01), Widdowson et al.
patent: 6077954 (2000-06-01), Cook et al.
patent: 6096773 (2000-08-01), Scott et al.
patent: 6197965 (2001-03-01), Cook et al.
patent: 6204294 (2001-03-01), Bryan et al.
patent: 6329523 (2001-12-01), Cook et al.
patent: 6750348 (2004-06-01), Bridger et al.
patent: 7091217 (2006-08-01), Bridger et al.
patent: 7098215 (2006-08-01), Yamazaki et al.
patent: 7176227 (2007-02-01), Yamazaki et al.
patent: 2004/0157818 (2004-08-01), Yanaka et al.
patent: 2004/0171638 (2004-09-01), Bridger et al.
patent: 2004/0254221 (2004-12-01), Yamazaki et al.
patent: 2005/0165063 (2005-07-01), Yamazaki et al.
patent: 2006/0128750 (2006-06-01), Bridger et al.
patent: 2006/0264434 (2006-11-01), Bridger et al.
patent: 2007/0208033 (2007-09-01), Yamazaki et al.
patent: 0 183 271 (1986-06-01), None
patent: 0 628 551 (1994-12-01), None
patent: 0 646 598 (1995-04-01), None
patent: 1268419 (1972-03-01), None
patent: 7-89988 (1995-04-01), None
patent: 98/05961 (1998-02-01), None
patent: WO 98/06397 (1998-02-01), None
patent: WO 99/33787 (1999-07-01), None
patent: WO 00/06086 (2000-02-01), None
patent: 00/56729 (2000-09-01), None
patent: WO 00/56729 (2000-09-01), None
patent: WO 01/10842 (2001-02-01), None
patent: WO 01/79168 (2001-10-01), None
patent: 02/22600 (2002-03-01), None
patent: WO 02/22600 (2002-03-01), None
patent: WO 02/94261 (2002-05-01), None
patent: 02/49993 (2002-06-01), None
patent: 02/062766 (2002-08-01), None
patent: WO 03/029218 (2003-04-01), None
patent: WO 2004/024697 (2004-03-01), None
Stella, Valentino J, Expert Opinion of Therapeutic Patents, Prodrugs as therapeutics, 2004 14(3): 277-280.
Wolff et al. (Burger's Medicinal Chemistry, 5th Ed., vol. 1, pp. 975-977, 1994).
Testa, Bernard, Biochemical Pharmacology, Prodrug Research: futile or fertile? 68 (2004) 2097-2106.
Ettmayer, Peter, Medicinal Chemistry, Lessons Learned from Marketed and Investigational Prodrugs, 47(10) (2004) 2394-2404.
Golub et al. Science (1999), vol. 286 531-537.
Lala et al. Cancer and Metastasis Reviews (1998), 17(1), 91-106.
Molino, M. et al., “CXCR4 on human endothelial cells can serve as both a mediator of biological responses and as a receptor for HIV-2,” Biochimica et Biophysica Acta (BBA), Molecular Basis of Disease, vol. 1500, pp. 227-240 (2000).
Saishin Idaku, vol. 53, No. 9, pp. 2031-2038 (1998) with English translation of abstract.
Nikkei Science, Oct., p. 26-37 (1998) with English version Bartlett, John G. et al, “Improving HIV Therapy,” Scientific American, pp. 84-89 (Jul. 1998).
Molecular Medicine, vol. 36, No. 9, pp. 1012-1017 (1999) with English translation of abstract.
Nikkei Science, Oct., pp. 42-49 (1998) with English version Baltimore, David et al, “HIV Vaccines: Prospects and Challenges,” Scientific American, pp. 78-83 (Jul. 1998).
Feng, Yu et al, “HIV-1 Entry Cofactor: Functional cDNA Cloning of a Seven-Transmembrane, G Protein-Coupled Receptor,” Science, 272, 872-877 (1996).
Bleul, Conrad C. et al, “The lymphocyte chemoattractant SDF-1 is a ligand for LESTR/fusin and blocks HIV-1 entry,” Nature, 382, 829-831 (1996).
Schols, Dominique et al, “Inhibition of T-tropic HIV Strains by Selective Antagonization of the Chemokine Receptor CXCR4,” J. Exp. Med., 186, 1383-1387 (1997).
Murakami, Tsutomu et al, “A Small Molecule CXCR4 Inhibitor that Blocks T Cell Line-tropic HIV-1 Infection,” J. Exp. Med., 186, 1389-1393 (1997).
Doranz, Benjamin J. et al, “A Small-molecule Inhibitor Directed against the Chemokine Receptor CXCR4 Prevents its Use as an HIV-1 Coreceptor,” J. Exp. Med., 186, 1395-1400 (1997).
Muller, Anja et al, “Involvement of chemokine receptors in breast cancer metastasis,” Nature, 410, 50-56 (2001).
Supplementary European Search Report dated Nov. 27, 2009 that issued with respect to European Patent Application No. 03795301.5.
Database Caplus Chemical Abstract Service, XP00255118, Abstract of JP 11-269146, Oct. 5, 1999.
Database Caplus Chemical Abstract Service, XP00255119, Abstract of JP 52-059794, May 17, 1977.
Kikumoto Shigeyuki
Matsui Ryo
Ono Masahiro
Saitou Atsushi
Sawa Tomohiro
Anderson Rebecca L
Greenblum & Bernstein P.L.C.
Kureha Corporation
Shterengarts Samantha L
LandOfFree
Amine-based compound and use thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Amine-based compound and use thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Amine-based compound and use thereof will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2735762